⌕
Aktis Oncology · AKTS · Nasdaq
Tenet 52 · Mixed
Compare
$16.16−2.77%At closeTenet 52 · Mixed
$16.16−0.46 (−2.77%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Aktis Oncology (AKTS) Stock

Aktis Oncology (AKTS) closed at $16.16 on Nov 16, 2026; its Tenet Score is 52 of 100 against 409 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

Key stats

Previous close
$16.16
Nov 16, 2026
Market cap
$899.3M
share price × the latest quarter's diluted weighted-average share count (vendor)
Dividend yield
0.00%
reinvests all
52-week range
13.96 – 34.19
low → high, since listing
Tenet Score
52/100
Mixed · 409 Healthcare peers

Industry: Pharmaceutical Preparations · see every company filed here →

Aktis Oncology Inc scores 52/100. Mixed. Strongest on financial health, quality is the soft spot versus 409 Healthcare peers. Insufficient inputs: Tenet 52 is built from 2 of 4 pillars, from 20% of its inputs. The pillars showing a dash had no data, and Growth is left out because no growth rate could be measured.

Tenet Score · vs sector

n=409
52/ 100
Mixed
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
—
Quality
29
Health
74
Growth
—

Factor grades

Not enough factor data to draw the radar yet.
Value—QualityFHealthBGrowth—Momentum—
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
—
Not meaningful: shareholders' equity is zero or negative.
P/S
142.4×
price to sales
ROE
—
Not meaningful: shareholders' equity is zero or negative.
Operating margin
−1149.5%
before interest and tax
Net margin
—
Not reported in the company's filings for this period.
Current ratio
7.37
fiscal 2025
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 3y
—
This growth figure starts in a period outside the history your plan includes.

The whole report, at a glance · every card is a live peek, click any to open the section

About Aktis Oncology Inc

We are a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The field of targeted radiopharmaceutica…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=409) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 38 US ETFs · top wrappers by weightSee all ETFs holding AKTS →

Similar-sized companies in Pharmaceutical Preparations

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

What sector and industry is Aktis Oncology in?

Aktis Oncology is in the Healthcare sector and the Pharmaceutical Preparations industry.

What is Aktis Oncology's Tenet Score?

Aktis Oncology's Tenet Score is 52 out of 100, ranked against 409 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.